Role of Methylenetetrahydrofolate Reductase Gene Polymorphisms (C677T, A1298C, and G1793A) in the Development of Early Onset Vasculogenic Erectile Dysfunction

Archives of Medical Research

Volumn 41, Issue 6, 2010, Pages 410-422

  Safarinejad, Mohammad Reza ^a,b   Safarinejad, Shiva ^a   Shafiei, Nayyer ^a  

^a Private Practice of Urology and Andrology   (Iran)

^b Urology Journal   (Iran)

Author keywords

Erectile dysfunction; Genetic; Methylenetetrahydrofolate reductase; MTHFR gene; Polymorphism

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LIPID; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADULT; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME METABOLISM; ERECTILE DYSFUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; VASCULOGENIC ERECTILE DYSFUNCTION;

ADULT; AGE OF ONSET; AMINO ACID SUBSTITUTION; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA PRIMERS; GENETIC ASSOCIATION STUDIES; GENOTYPE; HOMOCYSTEINE; HUMANS; IMPOTENCE, VASCULOGENIC; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; YOUNG ADULT;

EID: 78049440181     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.08.005     Document Type: Article

References (51)

1. Selvin E., Burnett A.L., Platz E.A. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007, 120:151-157.
2. Safarinejad M.R. Prevalence and risk factors for erectile dysfunction in a population-based study in Iran. Int J Impot Res 2003, 15:246-252.
3. Salonia A., Briganti A., Dehò F., et al. Pathophysiology of erectile dysfunction. Int J Androl 2003, 26:129-136.
4. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
5. Ueland P.M., Refsum H., Beresford S.A.A., et al. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000, 72:324-332.
6. Harpel P.C., Chang V.T., Borth W. Homocysteine and other sulphydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulphydryl compound metabolism. Proc Nat Acad Sci USA 1992, 89:10193-10197.
7. Motulsky A.G. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet 1996, 58:17-20.
8. Goyette P., Pai A., Milos R., et al. Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mamm Genome 1998, 9:652-656.
9. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995, 10:111-113.
10. Jacques P.F., Bostom A.G., Williams R.R., et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996, 93:7-9.
11. Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost 1997, 78:523-526.
12. Kang S.S., Zhou J., Wong P.W., et al. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988, 43:414-421.
13. Nygard O., Nordrehaug J.E., Refsum H., et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997, 337:230-236.
14. Kluijtmans L.A., van den Heuvel L.P., Boers G.H., et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996, 58:35-41.
15. Klerk M., Verhoef P., Clarke R., et al. MTHFR 677C->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002, 288:2023-20231.
16. van der Put N.M., Gabreels F., Stevens E.M., et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am J Hum Genet 1998, 62:1044-1051.
17. Weisberg I., Tran P., Christensen B., et al. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998, 64:169-172.
18. Rady P.L., Szucs S., Grady J., et al. Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas: a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet 2002, 107:162-168.
19. NIH Consensus Conference: Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993, 270:83-90.
20. Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychological Association, DSM-IV-TR, American Psychological Association, Washington, DC.
21. Rosen R.C., Riley A., Wagner G., et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997, 49:822-830.
22. Safarinejad M.R., Shafiei N., Safarinejad S. Relationship between three polymorphisms of methylenetetrahydrofolate reductase (MTHFR C677T, A1298C, and G1793A) gene and risk of prostate cancer: A case-control study. Prostate 2010 Jun 16, [Epub ahead of print].
23. Stephens M., Smith N.J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001, 68:978-989.
24. Stephens M., Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003, 73:1162-1169.
25. Eikelboom J.W., Lonn E., Genest J., et al. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999, 131:363-375.
26. Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998, 338:1042-1050.
27. Kaul S., Zadeh A.A., Shah P.K. Homocysteine hypothesis for atherothrombotic cardiovascular disease not validated. J Am Coll Cardiol 2006, 48:914-923.
28. Wald D.S., Law M., Morris J.K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325:1202.
29. Födinger M., Buchmayer H., Heinz G., et al. Effect of MTHFR 1298A->C and MTHFR 677C->T genotypes on total homocysteine, folate, and vitamin B(12) plasma concentrations in kidney graft recipients. J Am Soc Nephrol 2000, 11:1918-1925.
30. Winkelmayer W.C., Huber A., Wagner O.F., et al. Associations between MTHFR 1793G>A and plasma total homocysteine, folate, and vitamin B in kidney transplant recipients. Kidney Int 2005, 67:1980-1985.
31. Friedman G., Goldschmidt N., Friedlander Y., et al. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentrations. J Nutr 1999, 129:1656-1661.
32. Passaro A., Vanini A., Calzoni F., et al. Plasma homocysteine, methylenetetrahydrofolate reductase mutation and carotid damage in elderly healthy women. Atherosclerosis 2001, 157:175-180.
33. Brugada R., Marian A.J. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis 1997, 128:107-112.
34. Gudnason V., Stansbie D., Scott J., et al. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. EARS group. Atherosclerosis 1998, 136:347-354.
35. Graham I.M., Daly L.E., Refsum H.M., et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997, 277:1775-1781.
36. Dekou V., Whincup P., Papacosta O., et al. The effect of the C677T and A1298C polymorphisms in the methylenetetrahydrofolate reductase gene on homocysteine levels in elderly men and women from the British regional heart study. Atherosclerosis 2001, 154:659-666.
37. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288:2015-2022. The Homocysteine Studies Collaboration.
38. Voutilainen S., Rissanen T.H., Virtanen J., et al. Low dietary folate intake is associated with an excess incidence of acute coronary events: the Kuopio Ischemic Heart Disease Risk Factor Study. Circulation 2001, 103:2674-2680.
39. Stampfer M.J., Malinow M.R., Willett W.C., et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992, 268:877-881.
40. Meisel C., Cascorbi I., Gerloff T., et al. Identification of six methylenetetrahydrofolate reductase (MTHFR) genotypes resulting from common polymorphisms: impact on plasma homocysteine levels and development of coronary artery disease. Atherosclerosis 2001, 154:651-658.
41. Ono H., Sakamoto A., Mizoguchi N., et al. The C677T mutation in the methylenetetrahydrofolate reductase gene contributes to hyperhomocysteinemia in patients taking anticonvulsants. Brain Dev 2002, 24:223-226.
42. Xu X., Li J., Sheng W., et al. Meta-analysis of genetic studies from journals published in China of ischemic stroke in the Han Chinese population. Cerebrovasc Dis 2008, 26:48-62.
43. Yoo J.H., Hong S.B. A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants. Metabolism 1999, 48:1047-1051.
44. Andersen M.L., Guindalini C., Santos-Silva R., et al. Angiotensin-converting enzyme polymorphism and erectile dysfunction complaints in the Brazilian population. J Sex Med 2010 Apr 1, [Epub ahead of print].
45. Sinici I., Güven E.O., Serefoĝlu E., et al. T-786C polymorphism in promoter of eNOS gene as genetic risk factor in patients with erectile dysfunction in Turkish population. Urology 2010, 75:955-960.
46. Lee Y.C., Wu W.J., Liu C.C., et al. The associations among eNOS G894T gene polymorphism, erectile dysfunction, and benign prostate hyperplasia-related lower urinary tract symptoms. J Sex Med 2009, 6:3158-3165.
47. Lee Y.C., Huang C.H., Wang C.J., et al. The associations among eNOS G894T gene polymorphism, erectile dysfunction and related risk factors. BJU Int 2007, 100:1116-1120.
48. Erkan E., Muslumanoglu A.Y., Oktar T., et al. Polymorphism of endothelial nitric oxide synthase gene in patients with erectile dysfunction. J Sex Med 2006, 3:69-75.
49. Rosas-Vargas H., Coral-Vazquez R.M., Tapia R., et al. Glu298Asp endothelial nitric oxide synthase polymorphism is a risk factor for erectile dysfunction in the Mexican Mestizo population. J Androl 2004, 25:728-732.
50. Peskircioglu L., Atac F.B., Erdem S.R., et al. The association between intron 4 VNTR, E298A and IVF 23+10 G/T polymorphisms of ecNOS gene and sildenafil responsiveness in patients with erectile dysfunction. Int J Impot Res 2007, 19:149-153.
51. Khan S., Situ G., Decker K., et al. GoFigure: automated gene ontology annotation. Bioinformatics 2003, 19:2484-2485.